Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Kw-2450 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.34 |
| ▸ | IGF1R known ✓ | P08069 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 9/20 | 0.87 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.87 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kw-2450 Free Base SCHEMBL4314873 | 1.00 | AURKA (0.87) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL29637185 | 1.00 | AURKA (0.87) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313874 | 0.94 | AURKA (0.79) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313866 | 0.94 | AURKA (0.79) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL21275279 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL21275276 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL29379566 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4317450 | 0.93 | AURKA (0.76) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4317456 | 0.93 | AURKA (0.76) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313197 | 0.92 | AURKA (0.74) | AURKAAURKBCDK5CDK5R1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | claimed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012115226-A1 | THERAPEUTIC AGENT FOR CANCER | 協和発酵キリン株式会社 (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | INSR 4/4885IGF1R 1/4885AURKA 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.